Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EBITDA (2016 - 2025)

Rockwell Medical's EBITDA history spans 16 years, with the latest figure at -$398000.0 for Q4 2025.

  • For Q4 2025, EBITDA rose 23.31% year-over-year to -$398000.0; the TTM value through Dec 2025 reached -$4.7 million, down 871.55%, while the annual FY2025 figure was -$4.7 million, 871.55% down from the prior year.
  • EBITDA reached -$398000.0 in Q4 2025 per RMTI's latest filing, up from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.9 million in Q3 2024 to a low of -$8.4 million in Q4 2021.
  • Average EBITDA over 5 years is -$2.9 million, with a median of -$1.7 million recorded in 2023.
  • Peak YoY movement for EBITDA: surged 211.46% in 2024, then tumbled 361.94% in 2025.
  • A 5-year view of EBITDA shows it stood at -$8.4 million in 2021, then skyrocketed by 76.48% to -$2.0 million in 2022, then surged by 72.18% to -$547000.0 in 2023, then rose by 5.12% to -$519000.0 in 2024, then rose by 23.31% to -$398000.0 in 2025.
  • Per Business Quant, the three most recent readings for RMTI's EBITDA are -$398000.0 (Q4 2025), -$1.6 million (Q3 2025), and -$1.3 million (Q2 2025).